Please upgrade your browser.
Bernard Escudier, M.D., is the former chair of the genitourinary group of the Institut Gustave Roussy in Villejuif, France. Dr. Escudier’s research focuses on renal cell carcinoma, immunotherapy and on development of new therapeutic strategies.
Reese Park is working toward a day with no training wheels outside her Bridge Creek home. The 5-year-old is biking with her siblings, which includes quite a crew since she's the second oldest of six children. Reese's parents describe her as strong and quiet, so she seemed very out of character last July when she told her dad she needed medical help right away.
Lipid metabolism has been suggested to be associated with clinical outcomes of renal cell carcinoma (RCC). In this study, we aimed to investigate the relationship between preoperative cholesterol level (PCL) and postoperative outcomes of patients with localized RCC.
We're seeking your input on the planning of a large patient education meeting that would span two days and include presentations from leading experts from the major institutions...
The Kidney Cancer Association (KCA) invites proposals from young investigators for the 2018-2019 grant cycle. Young Investigator Award (YIA) abstracts are being accepted beginning October 30, 2017.
Kidney Cancer Research (KCRP) has been funded by the CDMRP for many years under various programs including the Peer Reviewed Medical Research Program, Tuberous Sclerosis Complex Research Program, and, most recently, by the Peer Reviewed Cancer Research Program (PRCRP). From FY10 through FY16, the PRCRP invested over $9.8M in kidney cancer research. In FY17 the US Congress directed $10M to kidney cancer research in the DoD appropriation, thus establishing the Kidney Cancer Research Program.
In a quest to end cookie-cutter health care, U.S. researchers are getting ready to recruit more than 1 million people for an unprecedented study to learn how our genes, environments and lifestyles interact...
The FY17 Defense Appropriations Act provides $10 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP) to support United States Army Medical Research Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).
Study Evaluating Opdivo in Combination with Yervoy Stopped Early for Demonstrating Overall Survival Benefit
The median PFS for the combination group was 11.6 months (95% CI: 8.71 to 15.51) versus 8.4 months (95% CI: 7.0 to 10.8) for the sunitinib group.
Amgen Inc. AMGN, -1.37% and Allergan AGN, -1.08% said Thursday that the Food and Drug Administration has approved their biosimilar version of Roche's Avastin for five types of cancer.
|NeonCRM by Neon One|